Todd Sheridan
Research Subjects
Todd Sheridan has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey H. Chuang
The Jackson Laboratory for Genomic Medicine 1 , Farmington, Connecticut
157 shared publications - Jill C. Rubinstein
The Jackson Laboratory for Genomic Medicine
157 shared publications - Sergii Domanskyi
The Jackson Laboratory for Genomic Medicine Farmington CT USA
157 shared publications - Brian J. Sanderson
Affiliation Department of Molecular Biosciences, University of Kansas, Lawrence, Kansas, United States of America
136 shared publications - Meenhard Herlyn
The Wistar Institute, Philadelphia, PA, USA
136 shared publications - Ali Foroughi pour
The Jackson Laboratory for Genomic Medicine, Farmington, CT
111 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma
Differentially expressed genes between pre-treatment (T0) and early-treatment (T1) that are significant in both models WM4007 and WM4237.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma
Differentially expressed genes between pre-treatment (T0) and early-treatment (T1) that are significant in both models WM4007 and WM4237.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis
Figure S11 from A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis
Figure S11 from A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 9 from Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma
Differentially expressed genes comparing T4 to T0 for RNA clusters 0, 1, 2, 5, 6 (WM4237).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 9 from Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma
Differentially expressed genes comparing T4 to T0 for RNA clusters 0, 1, 2, 5, 6 (WM4237).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma
Differentially expressed genes within T1, comparing lineage 1 to all others (WM4007).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma
Differentially expressed genes within T1, comparing lineage 1 to all others (WM4007).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma
Differentially expressed MAPK-pathway genes before and immediately after the initiation of treatment (T0 v T1) (WM4007).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma
Differentially expressed MAPK-pathway genes before and immediately after the initiation of treatment (T0 v T1) (WM4007).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma
Differentially expressed genes within T1, comparing lineage 4 to all others and excluding significant DEGs from the T1 lineage 1 to the rest comparison (WM4007).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma
Differentially expressed genes within T1, comparing lineage 4 to all others and excluding significant DEGs from the T1 lineage 1 to the rest comparison (WM4007).